Compounds useful for inhibiting chk1

A method of treating a cancer selected from the group consisting of a colorectal cancer, a breast cancer, a leukemia, a melanoma, a renal cell carcinoma, an ovarian cancer, a lung carcinoma, a cervical cancer, a colon cancer, and a prostate cancer which comprises administering to a patient in need thereof a therapeutically effective amount of a compound having a formula

• wherein:
• Y′ is O or S;
• W′ is
• optionally substituted with from one to four substituents selected from the group consisting of C1-6alkyl, aryl, N(R7)2, OR7, N3, CN, C(O)R7, C1-3alkylenearyl, C1-3alkyleneN(R2)2, halo, and
• Z′ is selected from the group consisting of:
• wherein
• Q′ is OR7;
• J′ is selected from the group consisting of CR8, NR8, O, and S;
• K′ is selected from the group consisting of CR9, NR9, O, and S;
• L′ is selected from the group consisting of CR10, NR10, O, and S;
• M′ is selected from the group consisting of CR11, NR11, O, and S;
• and provided when Z′ is a six-membered ring J′, K′, L′, and M′ cannot be O or S;
• wherein:
• R7 is C1-3alkyleneC3-8heterocycloalkyl;
• R8, R9, and R10 are each independently selected from the group consisting of hydrogen, halo, optionally substituted C1-6alkyl, C2-6alkenyl, OCF3, NO2, CN, NC, N(R7)2, OR7, CO2R7, C(O)N(R7)2, C(O)R7, N(R13)C(O)R7, N(R13)C(O)OR7, N(R7)C(O)OR7, N(R7)C(O)C1-3alkyleneC(O)R7, N(R7)C(O)C1-3alkyleneC(O)OR7, N(R7)C(O)C1-3alkyleneOR7, N(R7)C(O)C1-3alkyleneNHC(O)OR7, N(R7)C(O)C1-3alkyleneSO2NR7, CF3, C1-3alkyleneN(R12)SO2aryl, C1-3alkyleneN(R12)SO2heteroaryl, C1-3alkyleneOC1-3alkylenearyl, C1-3alkyleneN(R12)C1-3alkylenearyl, C1-3alkyleneN(R12)C1-3alkyleneheteroaryl, C1-3alkyleneN(R12)C(O)R7, C1-3alkyleneN(R12)C(O)C1-3alkyleneOR2, C1-3alkyleneN(R12)C(O)aryl, C1-3alkyleneN(R12)C(O)C1-3alkyleneN(R12)2, C1-3alkyleneN(R12)C(O)heteroaryl, C1-3alkyleneOR7, and SR7, wherein R7 is as defined above;
• R11 is selected from the group consisting of hydrogen, optionally substituted C1-6alkyl, and halo;
• R12 is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, aryl, heteroaryl, C1-3alkylenearyl, and SO2C1-6alkyl, or two R12 groups are taken together to form an optionally substituted 3- to 6-membered ring;
• and
• R13 is hydrogen;
• or a pharmaceutically acceptable salt thereof.